HER2 Nanoparticle Safety and Specificity Data Presented at AACR 2019

Matthew Wygant Blog

Marie Zhang, PhD, Vice President of Research and Clinical Development at Imagion Biosystems, presented the poster “HER2 Functionalized Nanoparticles Are Safe and Specific for in vivo HER2+ Breast Tumor Cell Detection” at the recently concluded 2019 Annual Meeting of the American Association for Cancer Research.

The poster presented by Dr. Zhang includes data from development and pre-clinical functionality studies of anti-HER2 antibody-conjugated nanoparticles for in vitro and ex vivo detection of HER2+ breast cancer tumor cells by magnetic relaxometry (MRX). The data suggest that Imagion Biosystems’ anti-HER2 antibody-conjugated nanoparticles are safe, provide targeted and specific delivery to cancerous tissue in vivo, and generate measurable signal on the magnetic relaxometry detection instrument.

This poster is now available to download: